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Abstract Anomalous expansion of a polyglutamine (polyQ)
tract in the protein ataxin-3 causes spinocerebellar ataxia
type 3, an autosomal dominant neurodegenerative disease.
Very little is known about the structure and the function of
ataxin-3, although this information would undoubtedly help to
understand why the expanded protein forms insoluble nuclear
aggregates and causes neuronal cell death. With the aim of
establishing the domain architecture of ataxin-3 and the role
of the polyQ tract within the protein context, we have studied
the human and murine orthologues using a combination of tech-
niques, which range from limited proteolysis to circular dichro-
ism (CD) and nuclear magnetic resonance (NMR) spectros-
copies. The two protein sequences share a highly conserved
N-terminus and di¡er only in the length of the glutamine repeats
and in the C-terminus. Our data conclusively indicate that atax-
in-3 is composed by a structured N-terminal domain, followed
by a £exible tail. Moreover, [15N]glutamine selectively labelled
samples allowed us to have a direct insight by NMR into the
structure of the polyQ region.
0 2003 Published by Elsevier B.V. on behalf of the Federation
of European Biochemical Societies.
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1. Introduction
Spinocerebellar ataxia type 3 or Machado^Joseph disease
(SCA3/MJD) is a member of the family of polyQ diseases, a
group of neurodegenerative disorders caused by expansion of
CAG trinucleotide repeats coding for polyQ in the gene prod-
ucts [1]. The polyQ region is the only feature shared by the
polyQ disease proteins, that show otherwise no sequence ho-
mology and carry the polyQ stretch at di¡erent positions [2].
The disorders develop when the repeat length exceeds a
threshold of 35^45 glutamines [1]. PolyQ expansions induce
protein aggregation and the formation of neuronal intranu-
clear inclusions, a hallmark of polyQ diseases [1]. Increasing
evidence suggests that protein misfolding and aggregation
play a crucial role in pathogenesis [3,4]. A structural charac-
terisation of the proteins involved in polyQ diseases would
therefore provide insights into the mechanisms of neurodegen-
eration.
Human ataxin-3, the protein related to SCA3/MJD, is a
ubiquitously expressed 41 kDa protein whose polyQ tract
contains 12^40 glutamines in normal individuals and 55^84
glutamines in the pathogenic form [2]. Ataxin-3 was found
in the genomes of several species, from nematodes to human,
including plants [5]. Alignment of the family shows a con-
served N-terminal block that corresponds to the sequence
motif named Josephin (residues 1^198 in the human protein)
[5]. The C-terminus, in contrast, is non-conserved throughout
di¡erent species and contains long stretches of low complexity
regions which include the polyQ tract, preceded by a highly
charged region.
Structural modelling of ataxin-3 predicted a mainly K-heli-
cal structure, with the polyQ tract residing in a long helix [5].
The proposed structure is in partial agreement with the esti-
mate of 35% K-helix, obtained by far-ultraviolet (UV) circular
dichroism (CD) [6]. The predicted conformation for polyQ,
however, is in contrast with most of the current hypotheses
based on modelling works or on experimental evidence on
ataxin-3 and model systems ([7] and references therein). These
works suggest a random coil or a L-sheet conformation for
solubilised polyQ tracts, and a L-sheet structure for polyQ
aggregates. The determination of the three-dimensional (3D)
structure of ataxin-3 could solve this debate.
In this article, we have structurally characterised native hu-
man ataxin-3, with the aims of de¢ning its domain architec-
ture and of investigating the conformation of the polyQ tract.
Murine ataxin-3 was also studied. This orthologue has 88%
sequence identity with the human protein, di¡ering from it in
the length of the polyQ tract (murine ataxin-3 has only six
glutamines) and in the C-terminus of the molecule (Fig. 1A).
Comparison of the two orthologues can therefore provide
novel information on the behaviour of polyQ tracts of di¡er-
ent lengths.
2. Materials and methods
2.1. Protein expression and puri¢cation
Murine ataxin-3 and two forms of non-expanded human ataxin-3,
containing respectively 18-residue and 26-residue glutamine repeats,
were produced. Human Q26 ataxin-3 was used for limited proteolysis
experiments only, since the low yields obtained were insu⁄cient for
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structural studies. All proteins were expressed in Escherichia coli
strain BL21 using the plasmids described below.
Human Q18 ataxin-3 cDNA was subcloned into a modi¢ed pET
plasmid vector (Stratagene) to produce a glutathione S-transferase
(GST)/ataxin-3 fusion protein, with a cleavage site for recombinant
Tobacco Etch Virus (rTEV). The protein was puri¢ed using a gluta-
thione Sepharose a⁄nity matrix (Amersham Biosciences). Human
Q26 ataxin-3 cDNA was obtained as described by Shehi et al. (sub-
mitted) and subcloned into a modi¢ed pET-11d plasmid vector. The
hexahistidine-tagged protein was puri¢ed using Ni-NTA agarose (Qia-
gen) followed by anion exchange. Murine ataxin-3 cDNA was ob-
tained as described in Shehi et al. (submitted) and subcloned into a
pGEX6P-1 vector (Amersham Biosciences). The GST fusion protein
was puri¢ed with glutathione Sepharose and cleaved from GST using
PreScission protease. For puri¢cation purposes, two, 14 and ¢ve res-
idues were added N-terminally to human Q18, human Q26 and mu-
rine ataxin-3, respectively.
Uniformly and selectively 15N-labelled samples were produced by
standard methods.
The ¢nal purity of all samples was higher than 95%, as assessed by
sodium dodecyl sulphate^polyacrylamide gel electrophoresis (SDS^
PAGE) and mass spectrometry. Protein concentrations were deter-
mined using UV absorption, with calculated extinction coe⁄cients
at 280 nm of 27 670 M31 cm31 and 27 550 M31 cm31 for human
and murine ataxin-3, respectively. Two features were consistently ob-
served in all samples: the proteins were prone to degradation and had
a tendency to aggregate non-speci¢cally (although the degree of ag-
gregation could be kept to a minor extent by careful sample handling)
and to be adsorbed on quartz cuvette walls.
2.2. CD and £uorescence spectroscopies
CD measurements were performed on a Jasco J-715 spectropo-
larimeter at 20‡C. Sample concentration was 2^4 WM and quartz
cuvettes (Hellma) with path lengths of 1 mm were used. Spectral
decomposition was achieved by combining the CONTIN, SELCON,
and CDSSTR methods [8].
2-p-Toluidinylnaphthalene-6-sulphonate (TNS) (Sigma) £uores-
cence spectra were recorded at 20‡C in quartz cuvettes using a
SPEX FluoroMax £uorimeter. Excitation was at 320 nm and emission
was scanned from 370 to 550 nm. The spectra were measured by
adding human or murine ataxin-3 (to a ¢nal concentration of 2^4
WM) to a 30 WM TNS solution.
2.3. Nuclear magnetic resonance (NMR) spectroscopy
All NMR spectra were recorded at 600 and 800 MHz 1H frequency
at 25‡C on Varian spectrometers. Experiments acquired included the
one-dimensional (1D) spectrum, two-dimensional (2D) 15N-HSQC
spectra, a 2D 15N-HSQC with refocussed INEPT periods and 1H
decoupling during t1 to obtain natural linewidths in the 15N dimen-
sion, a 15N T2-weighted HSQC with single ¢xed values of 10, 70 and
150 ms for the time allowed for T2 relaxation, 15N-(CLEANEX-PM)-
FHSQC experiment [18] and a TROSY [19] at 800 MHz.
The NMR experiments were performed in di¡erent bu¡ers, with
ionic strength varying from 20 to 200 mM, and at pH 6 and 7.4.
All the experiments led to similar conclusions.
2.4. Limited proteolysis
Thermolysin, trypsin, K-chymotrypsin, subtilisin and proteinase K
were obtained from Sigma. Proteolysis was carried out at 25‡C in 20
mM sodium phosphate, pH 8.0 (1 mM CaCl2 was added to the ther-
molysin proteolytic mixture). Protein concentration was 0.9 mg/ml
and the enzyme/substrate weight ratio was 1:100 for thermolysin,
K-chymotrypsin, subtilisin and proteinase K, and 1:500 for trypsin.
Proteolysis reactions were stopped by acidi¢cation with 0.1% tri-
£uoroacetic acid (Fluka) and the proteolytic mixtures were separated
by reverse phase high performance liquid chromatography (HPLC)
Fig. 1. A: Sequence alignment of human and murine ataxin-3. Sequence identity is indicated by stars. Decreasing degrees of sequence homol-
ogy are indicated by semi-columns and dots. The numbering refers to the sequence of murine ataxin-3. Arrows indicate the two major proteo-
lytic cleavage sites for each protein. B: Far-UV CD spectra of murine (dashed line) and human (continuous line) ataxin-3. C: 1D 1H NMR
spectra of murine (top) and human (bottom) ataxin-3.
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using a C4 Vydac column (4.6 U150 mm) (Separation Group, Hes-
peria, CA, USA). The fragments were analysed by SDS^PAGE, elec-
trospray ionisation mass spectrometry and N-terminal sequencing by
automated Edman degradation.
3. Results
3.1. Far-UV CD and NMR spectroscopies suggest that
ataxin-3 is only partially folded
Human and murine ataxin-3 were analysed using CD and
NMR spectroscopies. No signi¢cant di¡erences were observed
between the far-UV CD spectra of the human and murine
orthologues (Fig. 1B). Spectral deconvolution [8] indicates a
secondary structure content of 32% K-helix, 17% L-sheet, 20%
L-turn, and 31% random coil, in agreement with the results
obtained by Bevivino and Loll [6]. The signi¢cantly high per-
centage of random coil conformation estimated by this anal-
ysis suggests the presence of unstructured portions of the
molecule alongside one or more folded regions.
The presence of a structured core in human and murine
ataxin-3 was con¢rmed by 1D 1H NMR spectra, as shown
by the spectral dispersion over a range of 11 ppm and by the
presence of resonances (very similar in the human and murine
spectra) in the range from 31.0 to 0.8 ppm (Fig. 1C). Reso-
nances in this region arise from protons in close contact with
aromatic rings in structured conformations. Overall, the rela-
tively sharp linewidth of the well dispersed peaks (V25 Hz)
suggests the predominance of a monomeric species. Analytical
ultracentrifugation and gel ¢ltration data (not shown) are in
agreement with this observation, although they do not pro-
vide conclusive results, probably because of the tendency of
ataxin-3 to partial unspeci¢c aggregation (see Section 2).
Two main resonance types are clearly distinguishable in the
2D 15N spectra (HSQC) of murine and human ataxin-3 (Fig.
2A, B): well dispersed resonances typical of a folded confor-
mation are present together with sharp peaks which overlap in
the range 7.7^8.8 ppm (1H dimension) and 115^126 ppm (15N
dimension). These chemical shift values are typical of a ran-
dom coil conformation [9]. These results suggest that folded
regions must coexist with unstructured tracts. The presence of
regions with di¡erent mobility is further supported by T2
relaxation experiments, which show selective disappearance
of the well dispersed peaks ¢rst (see Additional materials).
In addition to these two types, very broad resonances are
also observable at chemical shifts typical of random coil spe-
cies. Their intensities are not a¡ected in TROSY experiments
or by decreasing the pH, suggesting that they arise from re-
gions of the proteins in a conformational exchange (see Addi-
tional materials).
The remarkable correspondence between the dispersed res-
Fig. 2. HSQC spectra of uniformly 15N-labelled murine (A) and human (B) ataxin-3. C: HSQC spectra of 15N glutamine selectively labelled hu-
man ataxin-3 and, for comparison, D: enlargement of B plotted at a higher level.
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onances in the human and murine spectra indicates that the
folded regions must comprise the highly homologous portions
of the two proteins and have the same conformation.
3.2. Limited proteolysis indicates the presence of
a protease-resistant N-terminal domain
To probe the domain organisation and the level of com-
pactness of ataxin-3, limited proteolysis experiments were per-
formed on the murine and human proteins. Several proteo-
lytic probes with di¡erent substrate speci¢ties were used,
namely trypsin, thermolysin, K-chymotrypsin, subtilisin and
protease-K. The patterns of proteolytic digestion of human
and murine ataxin-3 by trypsin, as detected by HPLC and
SDS^PAGE, are shown in Fig. 3. For both proteins, the in-
tact species are almost completely digested after 1 min of
incubation and fragments of approximately 30 and 20 kDa
are generated. As the proteolytic reaction proceeds, the 20
kDa fragments show remarkable resistance to degradation.
Mass spectrometry analysis shows that the most stable species
correspond to fragments 35^262 and 35^190 for murine
ataxin-3, and 314^262, 314^190 and 314^182 for human
ataxin-3 (negative numbers refer to the residues added N-ter-
minally to human and murine ataxin-3 for puri¢cation pur-
poses) (see Table in Additional materials). A similar pattern
was obtained using the other proteolytic probes. Interestingly,
the same pattern was also observed during spontaneous deg-
radation of aged ataxin-3 samples (see Additional materials).
These observations indicate that the N-terminal region of
both proteins is more resistant to proteolytic cleavage, whilst
the C-terminal region is signi¢cantly more prone to degrada-
tion. These conclusions fully agree with the NMR results and
show that ataxin-3 comprises an N-terminal folded core and
less compact regions at the C-terminus.
3.3. Glutamine selective labelling provides information about
the polyQ structure in ataxin-3
The conformation of the C-terminal tail, which comprises
the polyQ tract, was further investigated. The £uorescent
probe TNS was used to detect the presence of exposed hydro-
phobic surfaces. A signi¢cant increase in TNS £uorescence
and a blue shift of the emission maximum (440 nm) was
observed when human ataxin-3 was added to TNS (see Addi-
tional materials). Murine ataxin-3 gave rise to a comparable
e¡ect, with a shift of the emission maximum to 449 nm. The
data show that both proteins have hydrophobic residues that
are exposed to solvent and may therefore be located in £exible
regions of the proteins.
To identify the glutamine resonances, human ataxin-3 with
15N selectively labelled glutamines was produced. Comparison
of the HSQC spectra of uniformly and selectively labelled
human ataxin-3 shows that most of the glutamine backbone
amide resonances are concentrated within 8.5^7.9 ppm (1H
dimension) and 124^119 ppm (15N dimension) (Fig. 2C, D).
Although not all chemically equivalent, the resonances are
grouped in a relatively narrow region. The chemical shifts,
however, do not allow us to discriminate between K-helix,
L-sheet or random coil conformation. The side chain amides
are more informative, since they are all (with only one excep-
tion) concentrated between 7.5 ppm and 6.8 ppm (1H dimen-
sion) and 112 ppm (15N dimension). Comparison of the 1D
1H spectra of murine and human ataxin-3 con¢rms that these
peaks contain the contribution of the glutamine side chains in
the polyQ tract: the resonances at 7.49 and 6.83 ppm, that are
barely visible in the spectra of the murine protein, are clearly
observable as sharp peaks in human ataxin-3 (Fig. 1C). The
equivalence of these resonances, with chemical shifts corre-
sponding to random coil values, strongly suggests that the
polyQ side chain amides experience a similar chemical envi-
ronment. Further support to these observations was given by
TOCSY and CLEANEX-PM experiments that provide infor-
mation about £exibility and exposure to solvent (data not
shown). The H2N groups give rise to the only correlations
observable in a TOCSY experiment performed with human
ataxin-3 and have solvent exchange rates of the order of 12
s31. The data clearly show that the glutamines in the polyQ
tract are £exible and exposed to solvent.
4. Discussion
Using di¡erent complementary techniques, we have charac-
terised the domain architecture of ataxin-3. The possibility to
Fig. 3. A: HPLC analysis of proteolytic mixtures of human and
murine ataxin-3 with trypsin at incubation time 0 (intact protein),
25Q and 1P45Q, and 0, 50Q and 3P, respectively. B: SDS^PAGE analy-
sis of the proteolytic mixture of human (lines 2, 4, 6, 8, 10) and
murine (lines 3, 5, 7, 9, 11) ataxin-3 with trypsin. Aliquots from the
reaction mixture were taken after 0, 50Q, 1P45Q, 3P and 5P of incuba-
tion. Molecular weight markers are shown in line 1.
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analyse the behaviour of the human and murine proteins in
parallel proved essential in allowing us to reach our conclu-
sions. Such a comparative genomic approach will undoubt-
edly prove of increasing importance in structural and func-
tional genomic studies. Our results show that, in solution,
ataxin-3 is composed of a structured and compact N-terminal
domain followed by a more £exible C-terminus. These ¢nd-
ings are in good agreement with the pattern of sequence con-
servation among di¡erent species, that indicates the presence
of an N-terminal conserved motif, named Josephin (http://
www.sanger.ac.uk/Software/Pfam/server). Indeed, the bound-
aries of the 20 kDa N-terminal fragment identi¢ed by limited
proteolysis coincide with those indicated for this motif.
The protease accessible C-terminus comprises the polyQ
tract. While it is di⁄cult at this stage to identify conclusively
in the NMR spectrum the glutamine backbone amides in the
polyQ tract, comparison of ataxin-3 spectra with those of the
GST-polyQ model systems [10] suggests interesting di¡erences
and similarities. In the GST-polyQ spectra, most of the ob-
servable resonances could be con¢dently attributed to the
£exible polyQ tail, as those resonances arising from the
GST moiety are severely broadened owing to e⁄cient trans-
verse relaxation in systems of this molecular weight (V56
kDa). In contrast, the spectrum of ataxin-3 appears crowded,
indicating di¡erent hydrodynamic properties of ataxin-3 from
GST-polyQ and that ataxin-3 is a non-compact monomeric
species. Despite this di¡erence, the chemical shifts of the glu-
tamine side chains of ataxin-3 are remarkably similar both in
their value and in the lack of dispersion to those observed for
the GST-polyQ systems and are typical of a random coil
conformation. This conclusion, together with the indication
that the glutamine side chains are £exible, argues against
the possibility of a L-conformation for the polyQ tract, stabi-
lised by interactions across glutamine side chains [11]. Further
insights into the conformation of polyQ will be provided by
spectral assignment of the two orthologues. Production of the
isolated N-terminal domain will also allow us to discriminate
between glutamines in the polyQ tract and those in the rest of
the molecule. Work along this line is currently in progress in
our group.
While awaiting new data, we can draw some conclusions
about the shape of the protein. Independent but complemen-
tary evidence suggests that, in solution, unbound ataxin-3 is a
non-compact protein, as also shown by its tendency to under-
go C-terminal proteolytic degradation and partial unspeci¢c
aggregation. This observation is in agreement with the elon-
gated shape predicted for ataxin-3 by Bevivino et al. using
analytical ultracentrifugation [6]. TNS binding and the chem-
ical exchange observed in the NMR spectrum, two features
typical of molten globule states, also suggest that, when not
bound to other cellular components, the structure of ataxin-3
is much less compact than the one predicted by comparative
modelling [5]. It is however possible that the protein may
adopt a more compact structure only upon interaction with
other cellular partners, which could stabilise the fold of the
C-terminus. Ataxin-3 was shown to interact with the nuclear
matrix [12,13] and to bind to histones and several transcrip-
tional activators [14,15]. Moreover, ataxin-3 contains two
ubiquitin-interacting motifs [16] and binds to the ubiquitin-
like domain in the DNA repair proteins HHR23A and
HHR23B [17]. Expansion of the polyQ tract could interfere
with and change the interacting surfaces, thus preventing
proper folding and promoting aggregation of the exposed glu-
tamines. The structure determination of the folded domain of
ataxin-3 and the further characterisation of its interactions
with other cellular components will thus provide essential in-
formation on the protein’s function and on the role of the
polyQ expansion.
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